ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Targeted RNA N
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Programmable ZBTB7A RNA NMolecular cancer · 2026Article
- Beyond DNA editing: how Cas13 redefined programmable RNA manipulation and what still limits its therapeutic promise.Nucleic acids research · 2026Review
- The Role of NMedComm · 2026Review
- Harnessing a single molecule for dual bioorthogonal regulation of RNA function and m6A methylation.Nucleic acids research · 2026Article
- FTO-mediated m6A modification regulates the osteogenic differentiation of ADSCs by targeting FOXO1.Stem cell research & therapy · 2025Article
- Targeted RNA base editing for therapeutic: mechanisms and advances.Pharmaceutical science advances · 2025Review
- H3K27ac Is Essential for Human Naive Pluripotency Modulated by m6A-Driven EP300 Expression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Single-molecule direct RNA sequencing reveals the shaping of epitranscriptome across multiple species.Nature communications · 2025Article
- Enhanced or reversible RNA N6-methyladenosine editing by red/far-red light induction.Nucleic acids research · 2025Article
- Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- ALKBH5 in development: decoding the multifaceted roles of mFrontiers in molecular biosciences · 2025Review
- Precision Transcriptome Editing.ACS synthetic biology · 2024Review
- The regulatory role of mGenes & diseases · 2024Review
- Programmable RNA NPlant biotechnology journal · 2024Article
- Nurturing gut health: role of m6A RNA methylation in upholding the intestinal barrier.Cell death discovery · 2024Review
- Profiling the role of m6A effectors in the regulation of pluripotent reprogramming.Human genomics · 2024Article
- Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond.Cell death and differentiation · 2024Review
- RNA N6‑methyladenosine methyltransferase WTAP promotes the differentiation of endothelial progenitor cells.Experimental and therapeutic medicine · 2023Article
- CRISPR-based mFrontiers in cell and developmental biology · 2023Review
- Hierarchical self-uncloaking CRISPR-Cas13a-customized RNA nanococoons for spatial-controlled genome editing and precise cancer therapy.Science advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Deficiency of the N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.